Syncona performance slips in December quarter as Nightstar shares fall

Writer, Stock Market Wire
Wednesday, February 13, 2019 - 07:21

Healthcare company investor Syncona said its performance slipped over the December quarter due to a fall in the share price of portfolio company Nightstar.

For the three months through December, Syncona posted a total return of negative 6.6%.

However, over the nine months through December the company posted a total return of 23.9%.

Other portfolio company, Blue Earth Diagnostics, showed good sales momentum with US unit sales of Axumin for the treatment of prostate cancer rising 17% to of 7,575.

Nightstar, meanwhile, announced plans to initiate a phase 2/3 expansion study in its second programme for treating vision impairment.

'We are pleased with the strong progress across our companies over the period,' chief executive Martin Murphy said.

'As we look forward, we continue to see a strong pipeline of exciting opportunities where we can continue to build globally competitive companies around exceptional science.'


Related content

Syncona to direct more capital towards cash, bonds

Healthcare company investor Syncona said it was tilting investment strategy to focus more on conservative investments such as cash and bonds.

The company said it...

Tue, 12/03/2019 - 07:22


Syncona to collect proceeds of £254.6m from sale of portfolio company Nightstar

Syncona said it expected to collect £254.6m in proceeds from the agreed sale of portfolio company Nightstar to Biogen for $877m.

The offer, priced at...

Mon, 04/03/2019 - 07:47


Syncona invests £21.4m in immuno-oncology company Anaveon

Syncona said it had made a new commitment to immuno-oncology company Anaveon worth 28m Swiss francs (£21.4m).

The investment was made as part of a...

Tue, 26/02/2019 - 09:20


The benefits of highly-diversified investment trusts

Author: 

Given the return of equity market volatility, the threat to global growth from trade wars as well as political uncertainties, portfolio diversification should be front...

Thu, 07/02/2019 - 00:00


Syncona portfolio company Autolus commences new clinical trial

Life sciences company investor Syncona said portfolio company Autolus Therapeutics had dosed the first patient in a trial of a new therapy for treating lymphoma....

Mon, 03/12/2018 - 07:49